单位：[1]Stanford Cardiovascular Institute, Stanford, CA, USA.[2]Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.[3]Division of Cardiology,Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology,Wuhan,China.华中科技大学同济医学院附属同济医院大内科心血管内科内科学系[4]Cardiovascular Research Institute, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.[5]Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.[6]Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
The presence of cardiovascular comorbidities is linked with worse outcomes in patients with coronavirus disease 2019 (COVID-19), and COVID-19 can induce cardiovascular damage. In this Review, Wu and colleagues summarize the latest mechanistic and clinical studies that contribute to our current understanding of COVID-19-related cardiovascular disease. Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry, which is triggered by binding of the viral spike protein to angiotensin-converting enzyme 2. Clinical studies have also reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism. Potential drug-disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize the current understanding of COVID-19 from basic mechanisms to clinical perspectives, focusing on the interaction between COVID-19 and the cardiovascular system. By combining our knowledge of the biological features of the virus with clinical findings, we can improve our understanding of the potential mechanisms underlying COVID-19, paving the way towards the development of preventative and therapeutic solutions.
基金：
The
authors are supported by the AHA (17MERIT33610009),
Burroughs Wellcome Foundation IRSA 1015009 (J.C.W.) and
the JSPS Overseas Research Fellowship (M.N.).
第一作者单位：[1]Stanford Cardiovascular Institute, Stanford, CA, USA.[2]Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
通讯作者：
通讯机构：[1]Stanford Cardiovascular Institute, Stanford, CA, USA.[2]Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.[6]Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
推荐引用方式(GB/T 7714)：
Masataka Nishiga,Dao Wen Wang,Yaling Han,et al.COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives[J].NATURE REVIEWS CARDIOLOGY.2020,17(9):543-558.doi:10.1038/s41569-020-0413-9.
APA：
Masataka Nishiga,Dao Wen Wang,Yaling Han,David B. Lewis&Joseph C. Wu.(2020).COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.NATURE REVIEWS CARDIOLOGY,17,(9)
MLA：
Masataka Nishiga,et al."COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives".NATURE REVIEWS CARDIOLOGY 17..9(2020):543-558
：
医学